Semarion Raises £2M to Fix the Cell Models That Drug Discovery Relies On

Semarion, a Cambridge-based biotechnology company, has raised £2 million from Parkwalk Opportunities EIS Fund and the University of Cambridge Enterprise Fund to develop a new approach to cell models for drug discovery. The company is building technology that enables more physiologically relevant in vitro models — laboratory cell systems used to test drug candidates before they reach animals or humans — with the goal of improving the predictive accuracy of preclinical drug testing and reducing the catastrophic failure rate of clinical trials.

The drug discovery industry faces a profound and well-documented productivity challenge. Despite decades of investment in molecular biology, genomics, and high-throughput screening, the rate at which drug candidates that show promise in preclinical testing go on to succeed in clinical trials has remained persistently low — roughly 90 percent of candidates that enter Phase I clinical trials fail to reach patients. A significant share of these failures occur because the cellular and animal models used in preclinical research are poor representations of human disease, meaning that drugs which appear effective in the laboratory behave differently — or not at all — in patients.

A core part of this problem lies in the cell models used in drug discovery. The cell lines most commonly used in pharmaceutical research are typically cancer-derived cells adapted to grow in artificial conditions — flat plastic surfaces, synthetic media, constant environmental conditions — that bear little resemblance to the three-dimensional, dynamically variable environment in which cells actually exist in living tissue. These conditions cause cells to alter their gene expression, morphology, and behaviour in ways that can make drug responses measured in the laboratory unreliable guides to what will happen in a patient. Semarion's platform aims to address this by enabling cell models that better recapitulate the three-dimensional architecture and mechanical environment of human tissue, producing readouts that are more predictive of clinical outcomes.

The Cambridge investor base — Parkwalk, which manages EIS funds focused on university spinouts, and Cambridge Enterprise, the university's commercialisation arm — reflects the company's origins in Cambridge's strong biomedical engineering and cell biology research community. The funding will be used to develop the technology platform and validate its performance in drug discovery workflows in collaboration with pharmaceutical partners.

Sources

• Semarion — company website